Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)

Helsinki University Central Hospital (HUCH)

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Acute Kidney Injury

Treatments: Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT01314209

11102010

Details and patient eligibility

About

The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.

Full description

Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18
• Clinical need for sedation
• Acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures)

Exclusion criteria

• Severe bradycardia (HR < 50/min)
• AV conduction block II-III (unless pacemaker installed)
• Severe hepatic impairment (bilirubin > 101 umol/l)
• Pregnancy or lactation
• Age < 18

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

dexmedetomidine

Experimental group

Treatment:

Drug: Dexmedetomidine